SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A run to a 52-week high has traders focused on expected Q3 results and BRIUMVIs sales ramp; while some see earnings expectations driving the move, others speculate about a buyout or short covering, neither of which is confirmed.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Bitcoins selloff following reports of a major Binance security breach is the main pressure on Strategy, whose shares traders view as closely tied to BTC. The community is split between buying the dip and warning that crypto-security concerns, alongside Strategys revenue miss and CFO transition, could weigh further on the stock.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCath reimbursement could decline sharply in 2027 has driven a steep selloff, raising concerns about pricing and revenue for CorMedixs flagship product. Traders disagree on the severity: some view the warning as a major commercial risk, while others argue DaVitas outlook is preliminary and point to CMS estimates as a reason not to assume a sustained reimbursement collapse.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

Energy-sector strength and XLEs rally toward fresh highs are drawing attention, with traders tying the move to elevated oil prices and supply concerns around Middle East shipping and damaged refining capacity. The tone is broadly bullish, though some traders warn the sector looks extended and could pull back if tensions ease or oil prices retreat.

Amp (AMP) is a cryptocurrency launched in 2020and operates on the Ethereum platform. Amp has a current supply of 99,720,267,351.28921674 with 89,781,193,103.18022 in circulation. The last known price of Amp is 0.0006528 USD and is up 0.85 over the last 24 hours. It is currently trading on 193 active market(s) with $5,174,420.89 traded over the last 24 hours. More information can be found at https://amp.xyz.

AMP Token

AMP is drawing attention after a sharp rally and volume spike, with traders pointing to technical momentum and wondering whether the move can hold; no confirmed immediate catalyst is established in the discussion. Bullish posts cite Flexas payment infrastructure and AMPs collateral role, while skeptics warn the tokens past rallies have faded and question whether adoption will translate into demand.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costcos strength amid a rotation into defensive consumer staples has drawn attention, with traders pointing to resilient membership and digital sales as support. Bulls welcome the move, while skeptics argue the stocks premium valuation leaves little room for disappointment.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

Strives leveraged Bitcoin-treasury exposure is the main focus as shares fall sharply alongside crypto-market weakness. Bears cite the preferred-stock and ATM financing as risks to common shareholders, while bulls view the decline as a buying opportunity and point to continued Bitcoin accumulation and bullish call activity.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,105,365. The last known price of Bitcoin is 77,177.65528711 USD and is down -1.08 over the last 24 hours. It is currently trading on 12773 active market(s) with $46,266,908,298.36 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

A reported major Binance security breach is driving concern about exchange safety, possible withdrawals and selling pressure across crypto. Traders are divided between expecting further downside from shaken confidence and viewing Bitcoins relative resilience as a buying opportunity, arguing the breach affects the exchange rather than Bitcoins network.

The Coca-Cola Co. engages in the manufacturing and marketing of non-alcoholic beverages. It operates through the following segments: Europe, Middle East and Africa, Latin America, North America, Asia Pacific, Global Ventures, and Bottling Investments. The company was founded by Asa Griggs Candler on May 8, 1886 and is headquartered in Atlanta, GA.

Coca-Cola Co

Coca-Colas Q3 earnings beat and raised full-year outlook, supported by global volume growth, are driving attention alongside demand for defensive consumer staples. Traders are upbeat about the results and stock momentum, while some question softer North American demand and the elevated valuation.

Quantinuum Inc. is a quantum computing platform that offers solutions like hardware platforms, developer tools, application libraries and solution-targeted intellectual property (“IP”). The company was founded on January 20, 2026 and is headquartered in Broomfield, CO.

Quantinuum Inc. - Ordinary Shares - Class A

Quantinuum Inc.

Quantinuum shares are under pressure amid trader concerns that the Nov. 30 lockup expiration could increase selling, alongside a broader pullback in quantum stocks. Some see the decline as an overdone selloff and point to the companys technology progress and partnerships, while others remain worried about valuation and post-lockup supply.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Iovances updated IOV-LUN-202 non-small-cell lung cancer results and shift toward biomarker-selected development are driving attention: the broad-population data, immature durability and later filing timeline disappointed traders, while the strong response in a narrower subgroup has some investors arguing the selloff overstates the setback. The community also criticizes the confusing rollout and debates regulatory prospects and market size, with bullish posters pointing to the planned prospective study and the continuing melanoma business.

SLS, IOVA, IBRX Slump In October As Biotech Stocks Hold Steady: Virginia Pension Fund Raised Stakes In All 3

The decline appears tied to Iovances updated Phase 2 lung-cancer data: lifileucels response rate was 24.6% among 69 patients, while the 59.1% rate came from a retrospective biomarker-selected subgroup. Concerns about the broader results, immature durability data and a 2027 filing timeline were compounded by confusion around managements presentation.

GILD Beats Q3 Earnings on HIV Strength & Trodelvy Sales Growth

Gilead tops Q3 earnings and revenue estimates as HIV sales, Trodelvy and Livdelzi drive growth, prompting an increase in 2026 product sales guidance.

INSM Q3 Earnings Miss, Stock Soars on Sales Beat & Raised Guidance 

Insmed's third-quarter revenues surge 268%, fueled by strong Brinsupri sales, prompting a 15% stock rally and higher 2026 sales guidance.

Equity

Virginia Retirement Systems raised its stakes in all three stocks, with combined holdings worth nearly $3 million at September-end.

Dow, S&P 500, Nasdaq Futures Fall As Weak Tech Earnings Trigger Selloff: INTC, IOVA, SLS, AMZN Stocks In Focus

Markets are headed for a mixed close in October, with the Nasdaq likely to end lower, while the Dow and S&P 500 are headed to close in the green.

Illumina (ILMN) Q3 Earnings Beat Estimates

Illumina (ILMN) delivered earnings and revenue surprises of +5.88% and -0.76%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Amarin's Q3 Earnings Beat Estimates, Revenues Miss Mark

AMRN's Q3 2026 earnings surpass estimates despite declining revenues. Global Vascepa/Vazkepa demand grows 55% and cash reserves increase.

IOVA Stock Heads For Worst Day In Over 17 Months, Retail Says ‘Selling Is Not Done’ – What’s Driving The Fall?

Iovance reported updated results from its Phase 2 IOV-LUN-202 trial evaluating Lifileucel in patients with metastatic non-squamous non-small-cell lung cancer.


BHC Q3 Earnings Beat on Salix Growth, Stock Gains 9% as Outlook Rises

Bausch Health shares jump 9% as Q3 earnings top estimates, driven by Xifaxan-led Salix growth, improved profitability and raised 2026 guidance.

Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?

RXRX heads into Q3 earnings with key collaboration milestones, advancing clinical programs and upcoming pipeline updates that could shape its outlook.

Iovance Biotherapeutics (IOVA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Iovance Biotherapeutics (IOVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Extremely Bullish Sentiment

<ul class="summary-bullets"><li>China Universal and Mirae added to IOVA and IBRX, while other institutions cut positions.</li><li>IOVA plunged after updated Lifileucel lung-cancer data, despite stronger responses in a selected subgroup.</li><li>Sellas’ Regal trial reached its 80th event, triggering final analysis, with results expected this quarter.</li></ul><p>Sellas Life Sciences (SLS), Iovance Biotherapeutics (IOVA) and ImmunityBio (IBRX) are closing out a difficult October, even as recent filings reveal that Virginia Retirement&nbsp;System entered the month with larger stakes in all three companies.</p><p>So far this month,&nbsp;<a href="https://stocktwits.com/symbol/SLS">SLS</a> has fallen 18%,&nbsp;<a href="https://stocktwits.com/symbol/IOVA">IOVA</a> is down 35% and&nbsp;<a href="https://stocktwits.com/symbol/IBRX">IBRX</a> has lost 7%. All three lagged the&nbsp;<a href="https://stocktwits.com/symbol/XBI">SPDR S&amp;P Biotech ETF (XBI)</a>, which recovered from earlier weakness to trade nearly flat for the month.&nbsp;</p><h2 class="st-heading-2"><strong>Who Added And Who Cut Their Holdings In SLS, IBRX, And IOVA</strong></h2><div><figure class="table"><table class="ck-table-resized"><colgroup><col><col><col><col></colgroup><tbody><tr><td>Stock</td><td>Shares held as of Sept.30</td><td>Shares added</td><td>Increase</td></tr><tr><td>SLS</td><td>26,500</td><td>9,100</td><td>52%</td></tr><tr><td>IOVA</td><td>131,450</td><td>23,400</td><td>22%</td></tr><tr><td>IBRX</td><td>76,000</td><td>1,500</td><td>2%</td></tr></tbody></table></figure></div><p>The pension investor’s three positions were worth nearly $3 million combined at quarter-end.</p><p>Meanwhile, other institutions took different routes: China Universal and Mirae Asset each raised their IOVA and IBRX holdings by 16%, according to Fiscal.ai. Raiffeisen cut its IOVA stake by 26% to 280,000 shares, while Leonteq reduced its holding by 60% to 60,000 shares.</p><p>In SLS, Daiwa nearly exited, cutting its position by 99.9% to 100 shares. Wyoming reduced its stake by 92% to 1,635 shares, while SJS Investment Consulting held steady at 40,000 shares. Parkside’s eye-catching 32,650% increase came from a tiny base: its holding rose from two shares to 655.</p><h2 class="st-heading-2"><strong>Lung-Cancer Data Tests IOVA Bulls</strong></h2><p>Iovance plunged 36% to $9.56 on Thursday after updated Lifileucel lung-cancer data showed a 24.6% response rate in 69 patients, versus 25.6% previously reported in 39. Two responses await confirmation.</p><p>A retrospectively selected subgroup of 22 patients achieved a 59.1% response rate. “In the enriched subgroup, nearly six in ten patients responded, including two complete responses,” interim CEO Frederick Vogt said. Iovance plans to begin enrolling a prospective biomarker-selected cohort in November and targets a 2027 FDA submission for the broader lung-cancer program.</p><p>Lifileucel is already sold as Amtagvi for advanced melanoma. Demand for Amtagvi and Proleukin drove September’s increase in 2026 revenue guidance to $410 million to $420 million from a range of $350 million to $370 million.&nbsp;</p><h2 class="st-heading-2"><strong>A Key Trial Milestone Fails To Lift SLS</strong></h2><p>Sellas fell nearly 15% Wednesday and another 2.2% Thursday to $10.16 after its Phase 3 Regal leukemia trial reached the long-awaited 80th event, meaning 80 deaths.</p><p>The milestone triggers database lock, unblinding and final analysis, with preliminary topline results expected this quarter. “Reaching the 80th event represents a critical milestone in the Regal trial,” CEO Angelos Stergiou said.</p><p>Regal tests Galinpepimut-S (GPS) as maintenance treatment for patients in second complete remission. Results have not yet established whether GPS improved overall survival, the primary endpoint.&nbsp;</p><h2 class="st-heading-2"><strong>IBRX Slides Despite Approval And Trial Progress</strong></h2><p>ImmunityBio’s monthly decline comes despite the FDA’s recent expansion of Anktiva plus BCG’s approval to include BCG-unresponsive bladder cancer with papillary-only tumors, broadening its earlier indication involving carcinoma in situ.</p><p>The next catalyst is November’s readout from Quilt-2.005, a 366-patient trial comparing Anktiva plus BCG with BCG alone in patients who have not previously received BCG. ImmunityBio completed database lock last week and plans a fourth-quarter FDA submission, potentially moving treatment earlier in the disease course. CNBC’s Jim Cramer called ImmunityBio a “very good spec” earlier this week, citing biotech takeover activity.</p><h2 class="st-heading-2"><strong>How Do Retail Traders Feel About SLS, IBRX, IOVA?</strong></h2><p>On Stocktwits, IBRX led retail optimism with ‘extremely bullish’ sentiment and ‘extremely high’ message volume. SLS sentiment was ‘bullish’ amid ‘high’ message volume, while IOVA drew ‘bearish’ sentiment amid ‘low’ activity.&nbsp;</p><p>So far this year, IBRX has surged 341%, IOVA has gained 250% and SLS has climbed 169%, all outpacing XBI’s 30% advance.&nbsp;</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rklb-stock-rocket-lab-nasa-robot-repairs-neutron-advances-100th-electron-ships/cZUh0nZR9RY">RKLB Stock Tests Bulls’ Patience — Rocket Lab’s NASA Robot Eyes Repairs As Neutron Advances, 100th Electron Ships&nbsp;</a></p>

Representative Image (Photo credit: Getty Images)

iShares Biotechnology ETF

ImmunityBio Inc

SELLAS Life Sciences Group Inc

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

Investors are weighing the impact of a narrower, precision-medicine focused strategy in lung cancer clinical trials.

Speculation mounts regarding a potential acquisition of the company following recent share price volatility and interest from large pharma.

All eyes are on the upcoming earnings call to see if management can provide clarity on revenue guidance and trial timelines.

Disappointment over recent leadership communications has sparked significant debate about executive competence and strategic messaging.

Current Price	$8.48
Prev Close	$9.56
Open	$9.13
Dividend Yield	0.00%
50-Day Moving Average	$11.37
Beta	1.74
Avg. Volume	17.84M
PE Ratio	-11.76

52-Week High	$15.37
52-Week Low	$1.76
Market Capitalization	$3.84B
EPS (Annual)	-$1.09
Price to Book	5.22
Revenue Per Employee	$270,258.46

Feed

News

Sentiment

Earnings

Fundamentals

Info

IOVA Fundamentals